News
Alvotech announces Q1 2024 financial results webcast on May 22, 2024, at 8 a.m. EDT (12 p.m. GMT)
Alvotech
REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacturing of biosimilar medicines for patients around the world, today announced that it will release financial results from First quarter ended on March 31, 2024, after US markets close on Tuesday, May 21, 2024.
Alvotech will also host a conference call with analysts to present Q1 2024 financial results and recent business highlights on Wednesday, May 22, 2024, at 8 a.m. EDT (12 p.m. GMT). Live audio of the conference call will be webcast and available to members of the media, investors and the general public.
Information on how to access the webcast or participate via conference call is posted on the Alvotech investor website https://investors.alvotech.com. A direct link to the event is https://investors.alvotech.com/events/event-details/q1-2024-earnings. The webcast will also be archived and available to replay for 90 days after the event.
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused exclusively on developing and manufacturing biosimilar medicines for patients around the world. Alvotech seeks to be a global leader in the biosimilars sector, providing high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates intended to treat autoimmune diseases, ocular diseases, osteoporosis, respiratory diseases and cancer. Alvotech has formed a network of strategic business partnerships to provide global reach and leverage local expertise in markets including the United States, Europe, Japan, China and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s business partners include Teva Pharmaceuticals, a North American affiliate of Teva Pharmaceutical Industries Ltd. (USA), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland , Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. Hong Kong , Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd . (Thailand, Vietnam, Philippines and South Korea). Each business partnership covers a unique set of products and territories. Except as specifically set forth in this document, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information please visit www.alvotech.com. None of the information contained on the Alvotech website will be considered part of this press release.
The story continues
INVESTOR RELATIONS ALVOTECH AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, Senior Director
targettech.ir@alvotech.com
Please visit our investor portalit is ours website or follow us on social media at LinkedIn, Facebook, Instagram, X It is YouTube.
